Junmin Quan

Prof. Dr. Junmin Quan

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2018 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
YZYibo Zhang
Yibo Zhang
ZSZhen Sun
Zhen Sun
JPJianwen Pei
Jianwen Pei
QLQinhong Luo
Qinhong Luo
XZXin Zeng
Xin Zeng
JQJunmin Quan
Junmin Quan

1 May 2019 in Cancer Letters
Verified
Journal Article
Open access
JPJianwen Pei
Jianwen Pei
YZYibo Zhang
Yibo Zhang
QLQinhong Luo
Qinhong Luo
WZWenlv Zheng
Wenlv Zheng
WLWanxuan Li
Wanxuan Li
JQJunmin Quan
Junmin Quan
Cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is a key regulator in innate immunity and has emerged as a promising drug target in cancer treatment, but the utility of this pathway in therapeutic development is complicated by its dichotomous roles in tumor development and immunity. The activation of the STING pathway and the induced antitumor immunity could be attenuated by the feedback activation of IL-6/STAT3 pathway. Here we reported that STAT3 inhibition significantly enhanced the intensity and duration of STING signaling induced by the STING agonist c-diAM(PS)2. Such sensitization effect of STAT3 inhibition on STING signaling depended on STING rather than cGAS, which was mediated by simultaneously upregulating the positive modulators and downregulating the negative modulators of the STING pathway. Furthermore, the combination treatment with the STAT3 inhibitor and STING agonist markedly regressed tumor growth in syngeneic mice by increasing CD8+ T cells and reducing regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. Our work provides a rationale for the combination of STAT3 inhibitors and STING agonists in cancer immunotherapy.

2 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
XWXiaoquan Wang
Xiaoquan Wang
YWYouqiao Wang
Youqiao Wang
ACAnqi Cao
Anqi Cao
QLQinhong Luo
Qinhong Luo
DCDaoyuan Chen
Daoyuan Chen
JQJunmin Quan
Junmin Quan
Cyclic GMP-AMP synthase (cGAS) is an essential sensor of aberrant cytosolic DNA for initiating innate immunity upon invading pathogens and cellular stress, which is considered as a potential drug target for autoimmune and autoinflammatory diseases. Here, we report the discovery of a class of cyclopeptide inhibitors of cGAS identified by an in vitro screening assay from a focused library of cyclic peptides. These cyclopeptides specifically bind to the DNA binding site of cGAS and block the binding of dsDNA with cGAS, subsequently inhibit dsDNA-induced liquid phase condensation and activation of cGAS. The specificity and potency of one optimal lead XQ2B were characterized in cellular assays. Concordantly, XQ2B inhibited herpes simplex virus-1 (HSV-1)-induced antiviral immune responses and enhanced HSV-1 infection in vitro and in vivo. Furthermore, XQ2B significantly suppressed the elevated levels of type I interferon and proinflammatory cytokines in primary macrophages from Trex1-/- mice and systemic inflammation in Trex1-/- mice. XQ2B represents the specific cGAS inhibitor targeting protein-DNA interaction and phase separation and serves as a scaffold for the development of therapies in the treatment of cGAS-dependent inflammatory diseases.

1 August 2015 in Bioorganic Chemistry
Verified
Journal Article
Closed access
HYHong Yue
Hong Yue
FLFeng Lu
Feng Lu
CSChen Shen
Chen Shen
JQJunmin Quan
Junmin Quan

28 September 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZXZhiqiang Xie
Zhiqiang Xie
LLLiqing Lu
Liqing Lu
ZWZhenghua Wang
Zhenghua Wang
QLQinhong Luo
Qinhong Luo
YYYuchen Yang
Yuchen Yang
ZXZhen Xi
Zhen Xi

9 December 2009 in Organic Letters
Verified
Journal Article
Closed access
YCYi Cui
Yi Cui
ZJZhaodong Jiao
Zhaodong Jiao
JGJianxian Gong
Jianxian Gong
QYQuan Yu
Quan Yu
XZXiaofeng Zheng
Xiaofeng Zheng
ZYZhen Yang
Zhen Yang